GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (NAS:XOMA) » Definitions » Enterprise Value

XOMA (XOMA Royalty) Enterprise Value : $291.46 Mil (As of Jan. 19, 2025)


View and export this data going back to 1986. Start your Free Trial

What is XOMA Royalty Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, XOMA Royalty's Enterprise Value is $291.46 Mil. XOMA Royalty's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-18.95 Mil. Therefore, XOMA Royalty's EV-to-EBIT ratio for today is -15.38.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, XOMA Royalty's Enterprise Value is $291.46 Mil. XOMA Royalty's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $-18.71 Mil. Therefore, XOMA Royalty's EV-to-EBITDA ratio for today is -15.57.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, XOMA Royalty's Enterprise Value is $291.46 Mil. XOMA Royalty's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $9.71 Mil. Therefore, XOMA Royalty's EV-to-Revenue ratio for today is 30.01.


XOMA Royalty Enterprise Value Historical Data

The historical data trend for XOMA Royalty's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Royalty Enterprise Value Chart

XOMA Royalty Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 242.57 432.61 142.10 152.68 183.71

XOMA Royalty Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 128.01 183.71 264.31 253.56 287.43

Competitive Comparison of XOMA Royalty's Enterprise Value

For the Biotechnology subindustry, XOMA Royalty's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XOMA Royalty's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA Royalty's Enterprise Value distribution charts can be found below:

* The bar in red indicates where XOMA Royalty's Enterprise Value falls into.



XOMA Royalty Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

XOMA Royalty's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

XOMA Royalty's Enterprise Value for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XOMA Royalty  (NAS:XOMA) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

XOMA Royalty's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=291.463/-18.947
=-15.38

XOMA Royalty's current Enterprise Value is $291.46 Mil.
XOMA Royalty's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.95 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

XOMA Royalty's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=291.463/-18.714
=-15.57

XOMA Royalty's current Enterprise Value is $291.46 Mil.
XOMA Royalty's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.71 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

XOMA Royalty's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=291.463/9.711
=30.01

XOMA Royalty's current Enterprise Value is $291.46 Mil.
XOMA Royalty's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XOMA Royalty Enterprise Value Related Terms

Thank you for viewing the detailed overview of XOMA Royalty's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


XOMA Royalty Business Description

Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
Executives
Thomas M. Burns officer: Chief Financial Officer 2910 SEVENTH STREET, BERKELEY CA 94710
Owen Hughes director, officer: Interim CEO C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Bradley Sitko officer: Chief Investment Officer C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
James R Neal officer: VP Business Development 2910 SEVENTH STREET, BERKELEY CA 94710
Heather L Franklin director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVE E, SEATTLE WA 98102
Natasha Hernday director 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Bvf Ii Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Van Ness W Denman director C/O XOMA LTD, 2910 SEVENTH ST., BERKELEY CA 94710
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Deepshikha Datta officer: Chief Business Officer 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
John Varian director, officer: Director and CEO ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Matthew D Perry director, other: See Explanation of Responses ONE SANSOME STREET, 30TH FLOOR, SAN FRANCISCO CA 94104